Let's be clear: even if CYDY is sold for a pittance, most
Let's be clear: even if CYDY is sold for a pittance, most of us STILL all stand to make money, just nowhere near the amount that we thought we would/could/should based on the words of management.
As to treading water, look at the daily volume and SP. We've been between $.48 and $.50 for a long time now, nothing higher, nothing lower, not really.
We all hope that good news is coming. What does history show for CYDY? We wait and buy because we're allegedly "telegraphed" how great things are, and then it all falls apart at the last minute. Do I think that's the case now? I sure hope not, but this prolonged silence is getting too prolonged and a lot of us just feel stuck and abandoned after years of loyalty to a company that has promised to deliver and then doesn't quite do so.
If CYDY is sold for a pittance but I'm in the black or red, complaining about will still be a waste of time. We control nothing, we just wait and hope that something...anything management told us was right and true.
4
CytoDyn Inc (CYDY) Stock Research Links
Scroll down for more posts ▼
Top 10 Most Recent News Articles
Top 5 Most Recently Viewed Articles
Understanding Oscar Health's Recent Options Activity In the fast-paced world of trading, Oscar Health Inc’s (NYSE: OSCR) recent options activity has captured significant attention among savvy investors. Notably, there has been a notable bullish sentiment from wealthy investors towards this health insurance company. Tracking public options data reveals movements that...
Continue Reading
Better Choice Company Settles on Halo Asia Sale Better Choice Company, Inc. (BTTR), a leader in pet health and wellness, has recently reached a significant milestone by signing a definitive agreement to sell its Halo business in Asia. This sale is projected to generate total gross proceeds of $8.1 million, which encompasses $6.5 million in cash at the closing of the deal....
Continue Reading
Fastenal Prepares for Earnings Report Fastenal (NASDAQ: FAST) is gearing up to release its quarterly earnings report. Investors are keenly anticipating the upcoming announcement, as it offers a glimpse into the company's financial performance. This article provides essential insights and analysis for those eager to understand what to expect from Fastenal's announcement....
Continue Reading
Compass Therapeutics Advances Cancer Research BOSTON — Compass Therapeutics, Inc. (Nasdaq: CMPX), a promising player in the biotechnology sphere focused on developing innovative therapies for cancer, has made significant strides in its clinical research. The company has announced that the first patient has been dosed in a groundbreaking Investigator Sponsored Trial...
Continue Reading
Overview of the ECB Fine Imposed on LHV Group The European Central Bank (ECB) has recently informed AS LHV Group about a decision to levy an administrative fine amounting to EUR 405 thousand. This fine is linked to an error identified in the consolidated regulatory reporting for a specified timeframe. The issue arose from discrepancies in how the equity of LHV Bank...
Continue Reading